Management team

APIM Therapeutics’s management team is composed of the following experienced members:

Kostas Alevizopoulos

Kostas Alevizopoulos, PhD | Chief Executive Officer

Dr. Kostas Alevizopoulos brings more than 18 years of corporate expertise in the development and commercialization of therapeutic, diagnostic, medical device and OTC products. His personal track record combines investment, licensing and commercialization experience with significant research & development and regulatory expertise in both the preclinical and clinical space.

Before joining APIM Therapeutics, Kostas held various executive positions including: CSO of Gerolymatos International SA (GR), CEO of Medexis SA (GR), Head of Preclinical R & D of Biovista Inc. (US) and Head of R & D of Apotech SA (CH). Dr. Alevizopoulos consults for several biotech companies, academic institutes and government associations and is a co-founder of several biomedical companies. Finally, Kostas is also a partner of Ventac Partners, an international life science business development firm with affiliate offices in the US, Europe and Asia.

Dr. Alevizopoulos received his Biology degree from the University of Athens, Greece and his Ph.D. in Molecular Biology from the University of Lausanne, Switzerland. He has also conducted post-doctoral studies in the Swiss Institute of Experimental Cancer Research (Switzerland) and the Schering Plough Research Institute (USA) specializing in oncology research. He has published more than 25 peer review publications and he is co-inventor of several patent families. He is also trained in European Patent law (Strasbourg, France).

Marit Otterlei

Marit Otterlei, PhD | Chief Scientific Officer

Dr. Marit Otterlei is a Professor at the Department of Cancer Research and Molecular Medicine at the Faculty of Medicine, Norwegian University of Science and Technology (NTNU). Prof. Otterlei’s main focus in research is on proper function of biological processes, including DNA replication and repair. Prof. Otterlei has >60 peer reviewed international papers within the field including several review papers. She is a member of the Royal Norwegian Society of Science and Letter, 2006.

Dr. Otterlei received her M.Sc. in Chemistry in 1988 at the Norwegian Institute of Technology followed by a PhD degree in 1993 at the Institute of Cancer Research at the University of Trondheim. Dr. Otterlei was visiting scientist at Trancel Corporation, Santa Ana and Pancreas Transplant research, in Los Angeles, California, from 1990 through 1991. This position was followed by a Post.doc post at the Unigen Center for Molecular Biology at NTNU from 1994 through 1997. Dr. Otterlei became researcher and assistant professor at the institute of Cancer Research and Molecular Biology at NTNU in 1999, and stayed in this position until 2001, when she became visiting scientist at the Laboratory of Molecular Gerontology, National Institute of Aging, NIH, USA. Dr. Otterlei became Professor in medicine (molecular biology/molecular medicine) at the Department of Cancer Research and Molecular Medicine at NTNU in 2003.

Prof. Otterlei is a frequent presenter at international conferences. Besides the status as primary inventor of APIM, she brings extensive experience in the field of molecular understanding within the area to the company's board. Prof. Otterlei is a frequent presenter at international conferences. Besides the status as primary inventor of APIM, she brings extensive experience in the field of molecular understanding within the area to the company's board. For more information on Prf. Otterlei’s activities, please see her Publications.

Murray Yule

Murray Yule, MD PhD | Chief Medical Officer

Murray Yule is a board certified medical oncologist who trained in the United Kingdom and Houston, Texas. He gained his PhD in anticancer therapeutics at the University of Newcastle and he is a member of the Royal College of Physicians of the UK. Murray has more than seventeen years experience in the Pharma Industry and has a broad experience of the development of early anticancer therapeutics having successfully filed multiple INDs and CTA applications exploring previously unrecognized cancer targets. In addition, Murray has published more than twenty papers in his career in the cancer space.

Whilst working at Eisai, Murray led the team that successfully achieved global market approval of eribulin for the treatment of metastatic breast cancer. As the Medical Director of Astex Therapeutics, Murray was instrumental in its merger with Supergen Inc and ultimately its acquisition by Otsuka Pharmaceutical. As a former part of the BergenBio ASA management team Murray contributed to its successful IPO on the Norwegian exchange in 2017 followed by a further round of US investment in 2018. As a biotechnology medical officer Murray has successfully formed and driven translational and clinical collaborations with larger pharma including Novartis (small molecules leading to the development of ribociclib) and Merck (Immuno-oncology).

Hans Olav Minsas

Hans Olav Minsås, MBA. | Chief Financial Officer

Hans Olav Minsås is a business executive with more than 11 years experience in the financial sector. Currently serving as a Senior Analyst in Consulting Agency Impello (www.implello.no) focusing on investment appraisal, financial analysis, accounting and financial management, Mr. Minsås fulfills the role of Chief Financial Officer within APIM Therapeutics advising the company on various financial matters. Prior to his employment in Impello and APIM Therapeutics, Hans Olav Minsås served as an Analyst at Spare Bank 1 and an Auditor, Financial Services at KPMG.

Hans Olav Minsås is a graduate and holder of a Masters degree in Business Administration (MBA) from the Norwegian School of Economics.